Evidence map›Paper›PMID 39057763›Full record

ArticlePathogens (Basel, Switzerland)2024

Testing Hepatitis E Seroprevalence among HIV-Infected Patients in Greece: The SHIP Study.

Nikolina Antonopoulou, Georgios Schinas, Zoi Kotsiri, Olga Tsachouridou, Konstantinos Protopapas, Vasileios Petrakis, Emmanouil C Petrakis, Despoina Papageorgiou, Dimosthenis Tzimotoudis, Simeon Metallidis and 8 more

Abstract readMulticenter Study
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. HEV Infection in Beta-Thalassemia Patients.Pathogens (Basel, Switzerland) · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nikolina AntonopoulouDepartment of Internal Medicine and Infectious Diseases, University of Patras, 26504 Patras, Greece.
Georgios SchinasSchool of Medicine, University of Patras, 26504 Patras, Greece.ORCID 0000-0001-7963-1865
Zoi KotsiriDepartment of Public Health, University of Patras, 26504 Patras, Greece.
Olga TsachouridouDepartment of Internal Medicine and Infectious Diseases AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.ORCID 0000-0001-6503-0284
Konstantinos Protopapas4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, 12462 Athens, Greece.ORCID 0000-0001-5404-746X
Vasileios PetrakisDepartment of Internal Medicine and Infectious Diseases, University General Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Emmanouil C PetrakisDepartment of Internal Medicine and Infectious Diseases, University General Hospital of Heraklion, University of Crete, 71500 Heraklion, Greece.
Despoina PapageorgiouSchool of Medicine, University of Patras, 26504 Patras, Greece.
Dimosthenis TzimotoudisDepartment of Public Health, University of Patras, 26504 Patras, Greece.ORCID 0009-0006-2967-7156
Simeon MetallidisDepartment of Internal Medicine and Infectious Diseases AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Antonios Papadopoulos4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, 12462 Athens, Greece.
Markos MarangosDepartment of Internal Medicine and Infectious Diseases, University of Patras, 26504 Patras, Greece.
Emmanouil BarbounakisDepartment of Internal Medicine and Infectious Diseases, University General Hospital of Heraklion, University of Crete, 71500 Heraklion, Greece.
Diamantis P KofteridisDepartment of Internal Medicine and Infectious Diseases, University General Hospital of Heraklion, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0003-0255-5926
Periklis PanagopoulosDepartment of Internal Medicine and Infectious Diseases, University General Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Charalambos GogosSchool of Medicine, University of Patras, 26504 Patras, Greece.
Apostolos VantarakisDepartment of Public Health, University of Patras, 26504 Patras, Greece.
Karolina AkinosoglouDepartment of Internal Medicine and Infectious Diseases, University of Patras, 26504 Patras, Greece.ORCID 0000-0002-4289-9494

Funding

Gilead Asklepios Gilead Research Program 2019University of Patras K.Karatheodoris Research Fund 2018
6 · The paper itself

Abstract

Hepatitis E virus (HEV) poses significant health concerns worldwide, particularly among people living with HIV (PLWHIV), due to an increased risk of chronic infection and progression to cirrhosis in individuals with low CD4 cell counts. This study aimed to investigate the prevalence, chronicity potential, and risk factors of HEV infection among PLWHIV in Greece, where data are currently absent. A synchronic multicentric study encompassing five major Greek university hospitals was executed over 24 months, recruiting 696 PLWHIV participants. The prevalence of HEV IgG antibodies was 16.5%, with 8.6% showing evidence of acute HEV infection (HEV IgM). Active viral replication (HEV RNA) was present in 2.3% of the study population. Longitudinal analysis revealed that of the 25 initially anti-HEV IgM-positive individuals, only 3 seroconverted to IgG positivity, and among those with prior HEV RNA positivity (16), none showed evidence of active replication in subsequent tests. Comparative subgroup analysis highlighted the lack of significant differences in HIV-related parameters between HEV seropositive and seronegative individuals. Laboratory evaluations generally showed no significant disparities across most parameters; however, a higher seropositivity for Hepatitis A was observed in the HEV-positive subgroup. Our findings highlight a considerable prevalence of HEV among PLWHIV in Greece, with no observed cases of chronicity.

Indexed as

Hepatitis EHepatitis E virusHIV InfectionsAdultFemaleGreeceHepatitis AntibodiesHumansImmunoglobulin GImmunoglobulin MMaleMiddle AgedPrevalenceRisk FactorsRNA, ViralSeroepidemiologic StudiesHepatitis AntibodiesImmunoglobulin GImmunoglobulin MRNA, Viralantiretroviral therapycoinfectionGreecehepatitis E virushighly activeHIV infectionsseroprevalence

Identifiers

PMID39057763
PMCPMC11280285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.